AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

Search

Aflac Inc

Uždarymo kaina

SektoriusFinansų sektorius

99.07 0.54

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

98.51

Max

99.49

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.9B

29M

Pardavimai

-2B

3.5B

P/E

Sektoriaus vid.

15.68

25.916

Pelnas, tenkantis vienai akcijai

1.66

Dividendų pajamingumas

2.06

Pelno marža

0.84

Darbuotojai

12,694

EBITDA

-2B

145M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+6.77% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.06%

3.70%

Kitas uždarbis

2025-08-05

Kitas dividendų mokėjimo data

2025-09-01

Kita Ex Dividend data

2025-08-20

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.5B

55B

Ankstesnė atidarymo kaina

98.53

Ankstesnė uždarymo kaina

99.07

Naujienos nuotaikos

By Acuity

70%

30%

489 / 536 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Aflac Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 21:42; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025-08-04 21:21; UTC

Uždarbis
Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-08-04 19:15; UTC

Pagrindinės rinkos jėgos

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025-08-04 23:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-04 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Fed Stimulus Hopes

2025-08-04 23:28; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-04 23:28; UTC

Rinkos pokalbiai

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025-08-04 21:30; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 21:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025-08-04 21:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 20:25; UTC

Rinkos pokalbiai

India Hits Back Over Russian Oil Purchases -- Market Talk

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss $938M >RIG

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss/Shr $1.06 >RIG

2025-08-04 20:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:09; UTC

Uždarbis

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025-08-04 20:06; UTC

Uždarbis

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-08-04 19:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-08-04 19:28; UTC

Rinkos pokalbiai

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025-08-04 19:07; UTC

Rinkos pokalbiai

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025-08-04 18:27; UTC

Rinkos pokalbiai

Gold Climbs on Rate Cut Speculation -- Market Talk

Akcijų palyginimas

Kainos pokytis

Aflac Inc Prognozė

Kainos tikslas

By TipRanks

6.77% į viršų

12 mėnesių prognozė

Vidutinis 104.73 USD  6.77%

Aukščiausias 120 USD

Žemiausias 94 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aflac Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

12 ratings

3

Pirkti

7

Laikyti

2

Parduoti

Techninis įvertinimas

By Trading Central

105.92 / 109.14Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

489 / 536 reitingas Finansų sektorius

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Aflac Inc

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.